REVA announces clinical progress & anticipated $11.4 million cash receipt
REVA Medical announced it has enrolled over 200 patients in a
clinical study of its Fantom® sirolimus-eluting bioresorbable coronary scaffold and continues on track with its plans to commercialize Fantom. February 10, 2016